文献速递神经肿瘤

靶向酪氨酸代谢通路干预胶质瘤起始细胞

Targeting glioma-initiating cells via the tyrosine metabolic pathway.
PubMed 文献 · J Neurosurg · 2020-02-14

该研究对20例高级别胶质瘤组织和30例胶质瘤起始细胞球培养模型进行代谢分析,并结合Ivy GBM数据集,发现胶质母细胞瘤核心与边缘存在代谢异质性,酪氨酸代谢可能成为治疗靶点,尤其针对肿瘤核心;酪氨酸氨基转移酶(TAT)激活影响核心的治疗抵抗,选择性抑制酪氨酸代谢通路可能作为多模式胶质母细胞瘤治疗的辅助手段。

要点

  • 胶质母细胞瘤核心与边缘组织存在代谢异质性。
  • 酪氨酸代谢通路可能成为胶质母细胞瘤治疗靶点,尤其肿瘤核心。
  • 酪氨酸氨基转移酶(TAT)激活影响胶质母细胞瘤核心的治疗抵抗。

核心结论

  • 选择性抑制酪氨酸代谢通路可能作为多模式胶质母细胞瘤治疗的辅助手段,带来显著获益。

研究设计与样本

  • 对20例高级别胶质瘤组织和30例胶质瘤起始细胞球培养模型进行综合代谢分析,并结合Ivy GBM数据集。
  • 通过免疫组化在蛋白水平确认代谢变化。

主要发现

  • 在高级别胶质瘤组织和胶质母细胞瘤球培养模型中均发现代谢异质性。
  • 分析提示酪氨酸代谢可能作为胶质母细胞瘤的治疗靶点,尤其在肿瘤核心。
  • 酪氨酸代谢通路中酪氨酸氨基转移酶(TAT)的激活影响了胶质母细胞瘤核心的治疗抵抗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite an aggressive multimodal therapeutic regimen, glioblastoma (GBM) continues to portend a grave prognosis, which is driven in part by tumor heterogeneity at both the molecular and cellular levels. Accordingly, herein the authors sought to identify metabolic differences between GBM tumor core cells and edge cells and, in so doing, elucidate novel actionable therapeutic targets centered on tumor metabolism. METHODS: Comprehensive metabolic analyses were performed on 20 high-grade glioma (HGG) tissues and 30 glioma-initiating cell (GIC) sphere culture models. The results of the metabolic analyses were combined with the Ivy GBM data set. Differences in tumor metabolism between GBM tumor tissue derived from within the contrast-enhancing region (i.e., tumor core) and that from the peritumoral brain lesions (i.e., tumor edge) were sought and explored. Such changes were ultimately confirmed at the protein level via immunohistochemistry. RESULTS: Metabolic heterogeneity in both HGG tumor tissues and GBM sphere culture models was identified, and analyses suggested that tyrosine metabolism may serve as a possible therapeutic target in GBM, particularly in the tumor core. Furthermore, activation of the enzyme tyrosine aminotransferase (TAT) within the tyrosine metabolic pathway influenced the noted therapeutic resistance of the GBM core. CONCLUSIONS: Selective inhibition of the tyrosine metabolism pathway may prove highly beneficial as an adjuvant to multimodal GBM therapies.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Yamashita D, Bernstock JD, Elsayed G, et al. Targeting glioma-initiating cells via the tyrosine metabolic pathway. J Neurosurg. 2020. PMID: 32059178. doi:10.3171/2019.11.JNS192028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。